Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10014679 | 0.81 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2POLBKEAP1 | |
| SCHEMBL28291985 | 0.81 | KAT6A (0.51) | KAT6AMEN1KMT2ASMN1; SMN2GABRA1 | |
| SCHEMBL4238088 | 0.79 | KAT6A (0.54) | KAT6AGABRA1GABRB2CLCN2ALDH1A1 | |
| SCHEMBL4876639 | 0.79 | KAT6A (0.50) | KAT6AMEN1KMT2ASMN1; SMN2GABRA1 | |
| SCHEMBL5266668 | 0.79 | CES2 (0.61) | KAT6AMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL17758445 | 0.78 | KMT2A (0.46) | KAT6AMEN1KMT2ASMN1; SMN2KEAP1 | |
| SCHEMBL6216947 | 0.78 | PARP1 (0.50) | KAT6AMEN1KMT2AGABRA1GABRB2 | |
| SCHEMBL10299401 | 0.78 | KAT6A (0.49) | KAT6AMEN1KMT2AGABRA1GABRB2 | |
| SCHEMBL16951653 | 0.77 | KAT6A (0.48) | KAT6AMEN1KMT2AGABRA1GABRB2 | |
| SCHEMBL25078318 | 0.76 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2POLBKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | KAT6A 98/4885MEN1 638/4885KMT2A 126/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | KAT6A 98/4885MEN1 638/4885KMT2A 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.